• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.

作者信息

Bolis G, Scarfone G, Villa A, Parazzini F

出版信息

Gynecol Oncol. 2001 May;81(2):331-3. doi: 10.1006/gyno.2001.6179.

DOI:10.1006/gyno.2001.6179
PMID:11330974
Abstract
摘要

相似文献

1
Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.拓扑替康、卡铂和紫杉醇作为次优晚期上皮性卵巢癌一线治疗方案的II期试验。
Gynecol Oncol. 2001 May;81(2):331-3. doi: 10.1006/gyno.2001.6179.
2
Phase I study of alternating doublets of topotecan/carboplatin and paclitaxel/carboplatin in patients with newly diagnosed, advanced ovarian cancer.拓扑替康/卡铂与紫杉醇/卡铂交替双药方案用于新诊断晚期卵巢癌患者的I期研究
Gynecol Oncol. 2002 Apr;85(1):129-35. doi: 10.1006/gyno.2001.6581.
3
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.序贯双药联合方案治疗新诊断晚期卵巢癌的II期研究：拓扑替康与卡铂序贯紫杉醇与卡铂
Gynecol Oncol. 2004 Aug;94(2):533-9. doi: 10.1016/j.ygyno.2004.05.021.
4
Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.卡铂和拓扑替康用于晚期上皮性卵巢癌一线治疗时血液学毒性的序列依赖性：妇科肿瘤学组的一项I期研究
Gynecol Oncol. 2006 Nov;103(2):473-8. doi: 10.1016/j.ygyno.2006.03.014. Epub 2006 May 2.
5
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.卡铂和紫杉醇一线治疗晚期卵巢癌后使用拓扑替康的随机 III 期试验：AGO-OVAR 和 GINECO 的妇科癌症协作组试验
J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45. doi: 10.1093/jnci/djj296.
6
Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.紫杉醇/卡铂与拓扑替康/紫杉醇/卡铂治疗 FIGO 经手术切缘不满意的 III-IV 期上皮性卵巢癌患者：一项多中心随机研究。
Eur J Cancer. 2010 Nov;46(16):2905-12. doi: 10.1016/j.ejca.2010.06.124. Epub 2010 Jul 29.
7
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.一项关于腹腔内拓扑替康联合静脉注射卡铂和紫杉醇治疗晚期卵巢癌的I期研究。
Eur J Cancer. 2005 Mar;41(4):539-48. doi: 10.1016/j.ejca.2004.12.003. Epub 2005 Jan 11.
8
Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer.拓扑替康联合紫杉醇每周给药作为卵巢癌二线治疗方案
Cancer Chemother Pharmacol. 2007 Jun;60(1):123-8. doi: 10.1007/s00280-006-0383-6. Epub 2006 Nov 17.
9
Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.联合使用卡铂和紫杉醇作为晚期上皮性卵巢癌的一线治疗方案。
Gynecol Oncol. 2009 Aug;114(2):215-8. doi: 10.1016/j.ygyno.2009.04.008. Epub 2009 May 14.
10
A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer.
Gynecol Oncol. 2001 Dec;83(3):477-80. doi: 10.1006/gyno.2001.6399.

引用本文的文献

1
Topotecan for ovarian cancer.拓扑替康用于治疗卵巢癌。
Cochrane Database Syst Rev. 2008 Apr 16;2008(2):CD005589. doi: 10.1002/14651858.CD005589.pub2.
2
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.SCOTROC 2B研究：卡铂序贯多西他赛或多西他赛-伊立替康作为卵巢癌一线治疗的可行性
Br J Cancer. 2006 Jan 16;94(1):55-61. doi: 10.1038/sj.bjc.6602910.